This study is looking at how well certain medications work for people with migraine. These medications, called anti-CGRP drugs, include monoclonal antibodies like erenumab, galcanezumab, fremanezumab, and eptinezumab, or gepants like atogepant and rimegepant. Researchers want to see how these drugs affect your monthly headache and migraine days over about two years. You could be eligible if you are an adult diagnosed with migraine and have a prescription for one of these anti-CGRP drugs. This is an observational study, meaning researchers will watch how these drugs are used in real-world settings. The current status of this study is unclear.

Study design

This is an observational study with a planned enrollment of 700 participants. It is not specified if it is randomized or blinded.

What's involved

You will start an anti-CGRP medication and have visits every 6 months for two years. These visits will check how well the medication is working and if you have any side effects.

Compensation

Not stated in the trial record.

Follow-up

You will be observed for two years, with the primary endpoints measured through study completion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.